(MENAFN- GlobeNewsWire - Nasdaq) Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Licensing Deals in Pharmaceuticals 2020-2025" has been added to ResearchAndMarkets's offering.
The report provides access to licensing deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms. This report contains a comprehensive listing of licensing deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of licensing dealmaking and business activities. Chapter 1 introduces the report, while Chapter 2 offers an overview and analysis of licensing trends and discusses the merits of various deal types. Chapter 3 reviews the structure of licensing deals. Chapter 4 highlights leading licensing deals by headline value since 2020, providing links to SEC contract documents. Chapter 5 lists the top 25 most active licensing dealmakers, with links to detailed online deal records. Chapter 6 offers a detailed review of deals by company, therapy, and industry, with contract documents providing insights into agreed terms.
The deal directory includes a comprehensive listing of all licensing deals announced since 2020. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in licensing dealmaking since 2020. In conclusion, this report provides everything a prospective dealmaker needs to know about licensing alliances.
Licensing Deals in Pharmaceuticals provides the reader with the following key benefits:

• Understand deal trends since 2020
• Browse licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in licensing dealmaking
2.1. Introduction
2.2. Definition of licensing deal
2.3. Trends in licensing deals since 2020
2.3.1. Licensing dealmaking by year, 2020-2025
2.3.2. Licensing dealmaking by phase of development, 2020-2025
2.3.3. Licensing dealmaking by industry sector, 2020-2025
2.3.4. Licensing dealmaking by therapy area, 2020-2025
2.3.5. Licensing dealmaking by technology type, 2020-2025
2.3.6. Licensing dealmaking by most active company, 2020-2025
2.4. Reasons for entering into licensing partnering deals
2.5. The future of licensing deals
Chapter 3 - Overview of licensing deal structure
3.1. Introduction
3.2. Licensing agreement structure
Chapter 4 - Leading licensing deals
4.1. Introduction
4.2. Top licensing deals by value
Chapter 5 - Top 25 most active licensing dealmakers
5.1. Introduction
5.2. Top 25 most active licensing dealmakers
Chapter 6 - Licensing deals including contracts directory
6.1. Introduction
6.2. Licensing deals with contracts 2020-2025
Deal directory
Deal directory - licensing dealmaking by companies A-Z
Deal directory - licensing dealmaking by therapy area
Deal directory - licensing dealmaking by technology type
Companies Featured

• 3D Medicines
• Abbisko Therapeutics
• AbCellera Biologics
• Aceragen
• Adicet Bio
• Akeso Biopharma
• Allogene Therapeutics
• Amgen
• AnHeart Therapeutics
• Beam Therapeutics
• BeiGene
• Biogen
• Black Diamond Therapeutics
• Blueprint Medicines
• BridgeBio Pharma
• Caribou Biosciences
• Celsius Therapeutics
• Chimerix
• Citius Pharmaceuticals
• Compugen
• CRISPR Therapeutics
• Cytokinetics
• Dicerna Pharmaceuticals
• Edwards Lifesciences
• Editas Medicine
• Exscientia
• Fate Therapeutics
• Gemini Therapeutics
• Gilead Sciences
• Horizon Therapeutics
• ImmunoGen
• Incyte
• Intellia Therapeutics
• Ionis Pharmaceuticals
• Iovance Biotherapeutics
• Janssen Biotech
• Kiniksa Pharmaceuticals
• LianBio
• MacroGenics
• Moderna
• Novartis
• Otonomy
• Pfizer
• Reata Pharmaceuticals
• Regeneron Pharmaceuticals
• Sage Therapeutics
• Seagen
• Twist Bioscience
• Xencor

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN18112025004107003653ID1110359471